跳至主要内容
临床试验/ISRCTN80416929
ISRCTN80416929进行中(未招募)2 期

Randomised trial comparing total thyroidectomy, thyriod stimulating hormone (TSH) suppression and radioactive iodine ablation with total thyroidectomy and TSH suppression, in low-risk patients with thyroid cancer

niversity College London (UCL) (UK)0 个研究点目标入组 504 人开始时间: 2011年3月3日最近更新:
适应症

试验速览

阶段
2 期
状态
进行中(未招募)
发起方
入组人数
504

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Current inclusion criteria as of 06/06/2012
  • 1. R0 total thyroidectomy (in 1 or 2 stages, no residual disease present)
  • 2. Negative pregnancy test in females of child bearing potential
  • 3. Aged 16 years or over
  • 4. WHO performance status 0 ? 2, self caring
  • 5. Histological confirmation of differentiated thyroid carcinoma
  • 6. Papillary thyroid cancer:
  • 6.1 Non agressive histological features (small foci of agressive histology allowed)
  • 6.2 pT1b, 1-2cm intrathyroidal
  • 6.3 pT2, 2-4cm intrathyroidal
  • 6.4 pT3 intrathyroidal only
  • 6.5 Multifocal carcinoma
  • 7. Follicular thyroid cancer/Hürthle cell cancer (minimally invasive with capsular invasion only
  • 7.1 pT1b (1-2cm) pT2 (2-4cm) intrathyroidal
  • Previous inclusion criteria
  • 1. Negative pregnancy test in females of child bearing potential
  • 2. Aged 16 years or over, either sex
  • 3. World Health Organization (WHO) performance status 0 ? 2
  • 4. R0 total thyroidectomy (in 1 or 2 stages, no residual disease present)
  • 5. Histological confirmation of differentiated thyroid carcinoma
  • 6. Papillary thyroid cancer:
  • 6.1. Non aggressive histological features (small foci allowed)
  • 6.2. T1b, 1 - 2 cm, intrathyroidal
  • 6.3. T2, 2 - 4 cm, intrathyroidal
  • 6.4. T3, intrathyroidal
  • 6.5. No vascular invasion
  • 6.6. Multifocal microcarcinoma
  • 7. Follicular thyroid cancer/Hürthle cell cancer:
  • 7.1. Minimally invasive (capsular invasion only)
  • 7.2. Tumours 2 cm or less

排除标准

  • Current exclusion criteria as of 06/06/2012
  • 1. Papillary and Follicular carcinoma which is unifocal and <1cm in size
  • 2. Encapsulated Follicular Variant of Papillary Thyroid Cancer (EFVPTC) that is:
  • 2.1. non-invasive
  • 2.2. angio-invasive
  • 3. Anaplastic or medullary carcinoma
  • 4. R1 thyroidectomy
  • 5. Patients with:
  • 6. Aggressive Papillary thyroid cancer with the following features:
  • 6.1 Angio-invasive
  • 6.2 Widely invasive
  • 6.3 Poorly differentiated
  • 6.4 Anaplastic differentiation
  • 6.5 Tall cell
  • 6.6 Columnar cell
  • 6.7 Diffuse sclerosing variants
  • 7. Follicular thyroid cancer/Hürthle cell cancer with the following features:
  • 7.1. Angio-invasive
  • 7.2. Widely invasive
  • 7.3. Poorly differentiated
  • 7.4. Tumours greater than 4cm
  • 8. Incomplete resection/lobectomy
  • 9. Macroscopic and microscopic tumour invasion of locoregional tissues or structures
  • 10. Women who are lactating
  • 11. Patients who have had CT performed with iv contrast less than 3 months before ablation
  • 12. Previous treatment for thyroid cancer (except surgery)
  • 13. Previous malignancies with limited life expectancy or likely to interfere with the patient's ability to be able to comply with treatment and/or follow-up for at least 5 years
  • 14. Dysphagia
  • 15. Oesophageal stricture
  • 16. Active gastritis
  • 17. Gastric erosions
  • 18. Peptic ulcer
  • 19. Suspected reduced gastrointestinal motility
  • 20. Severe co-morbid condition/s that would prevent ablation including:
  • 20.1. Unstable angina
  • 20.2. Recent myocardial infarction or cerebrovascular accident (CVA)
  • 20.3. Severe labile hypertension
  • 21. Any patient who cannot comply with radiation protection including:
  • 21.1. patients with learning difficulties
  • 21.2. patients with dementia
  • 21.3. patients with a tracheostomy that require nursing care
  • 21.4. patients requiring frequent nursing/ medical supervision
  • Previous exclusion criteria
  • 1. Pregnant women or women who are breastfeeding
  • 2. Patients who have computed tomography (CT) performed with intravenous (iv) contrast less than 3 months before ablation
  • 3. Previous treatment for thyroid cancer (not including surgery)
  • 4. Incomplete resection/lobectomy
  • 5. Local or distant metastases at diagnosis
  • 6. Macroscopic and microscopic tumour invasion of locoregional tissues or structures
  • 7. Anaplastic or medullary carcinoma
  • 另有 4 项未显示

研究者

发起方
niversity College London (UCL) (UK)

相似试验

ION - Is ablative radiOiodine Necessary for low risk... | 临床试验